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Abstract – The recent pandemic caused by human inﬂuenza virus A(H1N1) 2009 contains ancestral gene
segments from North American and Eurasian swine lineages as well as from avian and human inﬂuenza
lineages. The emergence of this A(H1N1) 2009 poses a potential global threat for human health and the fact
that it can infect other species, like pigs, favours a possible encounter with other inﬂuenza viruses
circulating in swine herds. In Europe, H1N1, H1N2 and H3N2 subtypes of swine inﬂuenza virus currently
have a high prevalence in commercial farms. To better assess the risk posed by the A(H1N1) 2009 in the
actual situation of swine farms, we sought to analyze whether a previous infection with a circulating
European avian-like swine A/Swine/Spain/53207/2004 (H1N1) inﬂuenza virus (hereafter referred to as
SwH1N1) generated or not cross-protective immunity against a subsequent infection with the new human
pandemic A/Catalonia/63/2009 (H1N1) inﬂuenza virus (hereafter referred to as pH1N1) 21 days apart. Pigs
infected only with pH1N1 had mild to moderate pathological ﬁndings, consisting on broncho-interstitial
pneumonia. However, pigs inoculated with SwH1N1 virus and subsequently infected with pH1N1 had very
mild lung lesions, apparently attributed to the remaining lesions caused by SwH1N1 infection. These later
pigs also exhibited boosted levels of speciﬁc antibodies. Finally, animals ﬁrstly infected with SwH1N1 virus
and latter infected with pH1N1 exhibited undetectable viral RNA load in nasal swabs and lungs after
challenge with pH1N1, indicating a cross-protective effect between both strains.
inﬂuenza virus / swine H1N1 / human A(H1N1) 2009 / cross-protection
1. INTRODUCTION
Inﬂuenza viruses belong to the Orthomyxo-
viridae family and are characterized by a seg-
mented viral genome consisting of eight
single stranded RNA fragments of negative
polarity encoding 10 proteins [27]. In April
2009, a new A(H1N1) inﬂuenza virus was
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Article published by EDP Sciencesidentiﬁed containing a distinct combination of
gene segments from both North American and
Eurasian swine inﬂuenza lineages as well as
from avian and human lineages [8, 21], which
rapidly reached pandemic proportions. Most
human infections with this new swine-origin
H1N1 inﬂuenza virus variant, A(H1N1) 2009,
seem to be mild; however, there was a substan-
tial number of hospitalized young individuals
without previous underlying health problems,
attesting to the pathogenic potential of
A(H1N1) 2009 in humans.
Inﬂuenza viruses circulating in swine are
closely related to the human H1N1 and H3N2
strains and reports of sporadic cross-species
transfer of swine and avian inﬂuenza viruses
to humans have been documented repeatedly
during recent decades [18]. The mortality of
swine inﬂuenza virus (SIV) infected pigs is usu-
ally low, although morbidity may approach
100% [14]. Swine inﬂuenza is characterized
by sudden onset, coughing, respiratory distress,
weight loss, fever, nasal discharge and rapid
recovery [14]. Epithelial cells in the swine
respiratory tract have receptors for both avian
and mammalian inﬂuenza viruses [12]; thus,
pigs could potentially serve as ‘‘mixing ves-
sels’’ for the generation of new reassortant
strains.
Currently, few studies have assessed the
effect of the new pandemic A(H1N1) 2009
in pigs. No signs of disease were observed in
miniature pigs infected with A(H1N1) 2009,
although it replicated efﬁciently in the respira-
tory tract of these animals. According to this
study, the asymptomatic infection, despite efﬁ-
cient virus replication, might explain why this
new reassortant has never been found in swine
before it was ﬁrst identiﬁed in humans [13].
Another study analyzed replication dynamics,
clinical symptoms and virus transmission in
pigs infected with the novel A(H1N1) 2009.
The inoculated pigs started nasal virus shed-
ding from day 1 post-inoculation (PI) onwards
and developed generally mild symptoms
including fever, sneezing, nasal discharge,
and diarrhoea. In that study, contact pigs
became infected, shed virus and developed
clinical symptoms similar to the inoculated
animals [16].
The emergence of this novel human inﬂu-
enza virus A(H1N1) 2009 poses a potential glo-
bal threat for human health. Since the new virus
can infect other species, like pigs, a possible
encounter with other inﬂuenza viruses circulat-
ing in swine herds may favour the possibility of
generating new reassortants with higher viru-
lence. To date, there are several reports conﬁrm-
ing the diagnosis of A(H1N1) 2009 pandemic
inﬂuenza virus in pig herds in all continents
1.
In all cases, the herds are believed to have been
infected as a result of human-to-pig transmis-
sion. Therefore, the possibility that this novel
human inﬂuenza virus A(H1N1) 2009 could
affect a high percentage of swine herds has
unknown consequences, not only for animal
health but also for human health. A crucial
question is whether previous immunity to circu-
lating SIV protects pigs against pandemic
A(H1N1) 2009 virus. Kyriakis et al. [17]h a v e
recently shown that pigs dually infected with
some European SIV frequently exhibit cross-
reactive hemagglutination inhibitory (HI) anti-
bodies to pandemic A(H1N1) 2009 virus and
related North American SIV, suggesting that
pigs in Europe may have partial immunity to
the pandemic A(H1N1) 2009 virus. The ques-
tion of whether these antibodies would prevent
an A(H1N1) 2009 infection remained unan-
swered. Thus, the objectives of the current
study were (i) to experimentally investigate
whether or not a previous infection with circu-
lating H1N1 European avian-like swine inﬂu-
enza would confer protection to pigs which
later encounter the novel pandemic human
inﬂuenza virus A(H1N1) 2009 and (ii) to fur-
ther explore the pathological and immunologi-
cal parameters of this new A(H1N1) 2009
virus infection in pigs. The present study shows
that a single exposure to a H1N1 European
avian-like swine inﬂuenza protects pigs
against a consecutive challenge with the pan-
demic A(H1N1) 2009 virus even in the absence
of previous detectable cross-reactive HI
antibodies.
1 OIE, http://www.oie.int/eng/normes/mmanual/2008/
pdf/2.08.08_SWINE_INFLUENZA.pdf..
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2.1. Viruses
Two Inﬂuenza A virus isolates were used in this
study: the European avian-like swine A/Swine/
Spain/53207/2004 (H1N1) isolated in 2004
(GenBank accession number CY010587) (hereafter
referred to as SwH1N1) and the new human
A/Catalonia/63/2009 (H1N1) inﬂuenza virus iso-
lated in 2009 (GenBank accession numbers
GQ464405-GQ464411 and GQ168897) (hereafter
referred to as pH1N1). SwH1N1 was generously
donated by Laboratorios HIPRA (Spain) and it
was propagated following standard procedures by
infecting Madin-Darby canine kidney (MDCK) cells
cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% foetal bovine
serum (FBS) (ref. 23 OIE). pH1N1 was isolated
from a patient at the Hospital Clinic, Barcelona,
Spain, and was propagated at 37.5  C in the allan-
toic cavities of 11 day-old embryonated chicken
eggs originating from a commercial speciﬁc-patho-
gen-free (SPF) ﬂock (GDdeventer)
1.B o t hv i r u s e s
were titrated in MDCK cells, with the aid of trypsin
in the post-infection media, and virus titre was cal-
culated by the Reed and Muench method [19].
2.2. Animals
Twenty-two snatch-farrowed, colostrum-deprived
Large White · Landrace piglets were obtained from
a herd with a standard health status. Sows were
seropositive to porcine reproductive and respiratory
syndrome virus (PRRSV) and SIV, and seronegative
to Aujeszky’s disease virus. Piglets were obtained at
the moment of delivery, immediately dried and
umbilical cords clamped, cut and disinfected with
an iodine solution. Piglets were fed ad libitum dur-
ing the ﬁrst two days with the milk substitute Pata-
vie Porc (Oriane-Celtilait, Lesneven, France).
Afterwards, animals received Startrite 100 (SCA
Ibe ´rica S.A., Mequinenza, Spain) mixed with milk
or as dry meal from 10–15 days of age. Antibiotics
administered in the feed included 205 000 UI of
colistin (1 g of colimicine
 , Laboratorios SP Veteri-
naria, in 1.5 L of milk) during the ﬁrst week of age
and 1.7 mg of enroﬂoxacin (Baytril oral solution
0.5%, Bayer Animal Health, Leverkusen, Germany)
per kg body weight/day during the ﬁrst two weeks
of age. All piglets were housed in an experimental
isolation room at the biosafety level 3 facilities of
t h eC e n t r ed eR e c e r c ae nS a n i t a tA n i m a l( C R e S A ,
Barcelona, Spain). Animal care and procedures were
in accordance with the guidelines of the Good
Laboratory Practices (GLP) and under the supervi-
sion of the Ethical and Animal Welfare Committee
of the Universitat Auto `noma de Barcelona.
2.3. Experimental design
At the age of 40 days, pigs were randomly
distributed into four groups, namely Mock/Mock
(n = 6), SwH1N1/Mock (n = 4), Mock/pH1N1
(n = 8) and SwH1N1/pH1N1 (n = 4) balanced by
sex and weight. Group Mock/Mock pigs were intra-
nasally inoculated with 3.5 mL of MEM (half of the
amount in each nostril) on days 0 and 21 of the
experiment. Group SwH1N1/Mock animals were
intranasally inoculated with 3.5 mL of a suspension
containing 10
7.04 tissue culture infectious doses
50% (TCID50) per mL of SwH1N1 on day 0 and
received the same volume of MEM on day 21. Pigs
from group Mock/pH1N1 received the abovemen-
tioned amounts of MEM on day 0 and 10
6.15 TCID50
per mL of pH1N1 on day 21. Finally, pigs of group
SwH1N1/pH1N1 were inoculated with both viruses,
SwH1N1 on day 0 and pH1N1 on day 21, using the
same route and dose mentioned for previous groups.
Inordertostudytheeventstakingplaceattheearly
stages of infection with pH1N1, two Mock/Mock and
two Mock/pH1N1 piglets were euthanized with an
intravenous overdose of sodium pentobarbital on days
2a n d4a f t e rp H 1 N 1i n o c u l a t i o n( d a y s2 3a n d2 5P I ) .
All the remaining pigs in each group (2 animals of
Mock/Mock group and 4 animals in each of the
remaining groups) were euthanized on day 28 PI.
2.4. Clinical records and sampling procedures
Pigs were clinically monitored daily for the whole
experimental period, with emphasis on potential
respiratory disorders (coughing, sneezing and thump-
ing) as well as systemic signs (depression, reluctance
to move and fever). Speciﬁcally, rectal temperatures
w e r et a k e no nd a y s1 ,2 ,3 ,5a n d7a f t e rb o t hv i r a l
inoculations, and also after 10 and 15 days post-
SwH1N1 inoculation.
Nasal swabs were taken on days 1, 2, 4, 6, 10, 21,
22, 23, 25 and 28 PI, placed in 1 mL of PBS and fro-
zen at  80  C until further use. Complete necropsy
was done on each animal, with special emphasis on
the respiratory tract. Gross lung lesions were assessed
for the presence or absence of pulmonary cranio-
ventral multifocal consolidation and when present,
extension was recorded. Right lung was used to per-
form a broncho-alveolar lavage (BAL) using 200 mL
of PBS (animals from groups Mock/Mock and
SIV cross-protection on A(H1N1) 2009 in pigs Vet. Res. (2010) 41:74
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thological and virological studies (animals from all
experimental groups). Speciﬁcally, samples from
lung (apical, middle and diaphragmatic lobes), nasal
turbinate, nasal septae, trachea and tonsil were col-
lected and ﬁxed by immersion in 10% buffered for-
malin. Additional lung tissues (apical and cardiac
lobes) were frozen at  80  C until their use for viral
RNA extraction.
2.5. Pathological procedures
Fixed tissue samples were dehydrated through
graded alcohols, embedded in parafﬁn and stained
with hematoxylin-eosin. Each tissue was microscop-
ically studied for the presence of inﬂammatory
lesions. In the lung, broncho-interstitial pneumonia
(BIP) intensity was assessed by means a semi-quan-
titative scoring (0 to 3, indicating lack of, mild, mod-
erate or severe pneumonia lesions, respectively).
2.6. Antibody detection
Anti-inﬂuenza A virus nucleoprotein (NP) anti-
body levels were studied in serum using the ID
Screen
  Inﬂuenza A Antibody Competition ELISA
(ID-Vet, Montpellier, France) following manufac-
turer’s instructions on days 0, 21 and 28 PI.
Detection of speciﬁc IgG and IgA in nasal swabs,
serum and BAL was performed modifying the ID
Screen
  Inﬂuenza A Antibody Competition ELISA
with a goat anti-porcine IgG (Fc):HRP (Serotec
AAI41P) antibody at 1:100 000 dilution or a goat
anti-porcine IgA:HRP (Serotec AAI40P) antibody
at 1:10 000 dilution as secondary antibodies. Nasal
swabs and BAL samples were used neat in the
ELISA assay whereas serum samples were used at
1/100 dilution. Fifty lL of each sample or serum
dilutions were used in the ELISA assay.
Hemagglutination-inhibition (HI) assay was used
to measure antibody titres from serum samples at
days 0, 21 and 28 PI. The HI test was performed
according to standard procedures [25]. The test was
standardized at 4 hemmagglutinin units (HAU). To
remove non-speciﬁc inhibitors of hemagglutination
and natural agglutinins of sera, samples were treated
with receptor-destroying enzyme (RDE) from Vibrio
Cholerae (Sigma, St. Louis, MO, USA) overnight,
inactivated at 56  C for 60 min and adsorbed into
chicken red blood cells at 50% and 4  C. The starting
dilution was 1:20.
2.7. Hydrolysis probe and primer sets
The two inﬂuenza viruses used in this study and
all the available European avian-like swine and the
new human inﬂuenza virus A(H1N1) 2009 M gene
sequences were downloaded, aligned from the Inﬂu-
enza Viruses Resource
2 a n dt h e nc o m p a r e dt ot h eM
gene primer and probe sequences previously reported
[22]. Three mismatches were identiﬁed for the Euro-
pean avian-like SIV sequences and four in the new
human inﬂuenza virus A(H1N1) 2009 sequences in
the target sequence of the primer M-124. Also, one
mismatch was detected in the target sequence of
the M+64 probe affecting the European avian-like
SIV ampliﬁcation. Taking all this information into
account, primers and probes were modiﬁed to
improve the European avian-like SIV detection
Table I. Primers and probes used for TaqMan one-step qRT-PCR.
IAV Primer/probe Concentration
(lM)
Sequence (50-30) Reference
European
avian-like
swine
M+25 0.9 AGA TGA GTC TTC TAA CCG AGG TCG
M-124 E-A-L-S 1.8 TGC AAA RAC AYC TTC CAG TCT CTG This study
M+64 E-A-L-S 0.4 FAM
a- TCR GGC CCC CTC AAA GCC GA-
TAMRA
b
This study
A(H1N1)
2009
M+25 0.9 AGA TGA GTC TTC TAA CCG AGG TCG [16]
M-124 human09 0.9 TGC AAA GAC ACT TTC CAG TCT CTG This study
M+64 0.2 FAM- TCA GGC CCC CTC AAA GCC GA-
TAMRA
[16]
a FAM, 6-carboxylﬂuorescein.
b TAMRA, 6-carboxyltetramethyl rhodamine.
2 http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.
html.
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virus A(H1N1) 2009 detection in the present work
were different from those of recent reports [28],
although they were also based on previously reported
M gene primer and probe sequences [22]. Primers
a n dp r o b e su s e di nt h i ss t u d y( Tab. I) were synthe-
sized by Tib Molbiol (Berlin, Germany).
2.8 Quantitative RT-PCR (RT-qPCR)
SwH1N1 and pH1N1 viral loads in nasal swabs,
lung tissue and BAL were assessed following a Taq-
Man one-step RT-qPCR in Fast7500 equipment
(Applied Biosystems, Foster City, CA, USA). Viral
RNA was extracted with QIAamp viral mini kit
(Qiagen, Valencia, CA, USA) obtaining 60 lLo f
eluted viral RNA. The M fragment ampliﬁcation
was carried out using the primers and probe concen-
trations indicated in Table I a n dO n e - S t e pR T - P C R
Master Mix Reagents (Applied Biosystems) follow-
ing the manufacturer’s instructions using 5 lLo f
eluted RNA in a total volume of 25 lL. The ampli-
ﬁcation conditions were as follows: reverse transcrip-
tion at 48  C for 30 min; initial denaturation reaction
at 95  C for 15 min and 40 PCR-cycles of 95  C
15 s and 60  C1m i n .
Standard curves and quantiﬁcation were achieved
by prior ampliﬁcation of a 99 bp fragment of the M
gene using both aforementioned strains as templates,
primers described in Table I and the One-Step RT-
PCR reagents (Qiagen) following the manufacturer’s
instructions, using 5 lL of eluted RNA in a total vol-
ume of 25 lL. The ampliﬁcation conditions were the
following: reverse transcription at 50  C for 30 min;
initial denaturation reaction at 95  C for 15 min and
40 PCR-cycles of 94  C3 0 s ,5 5  C1 m i na n d
72  C 1 min. The obtained M gene fragment ampli-
con was cloned into pGEMT vector (Promega
Madison, WI, USA) and transformed by heat shock
in Escherichia coli competent cells (Invitrogen,
Paisley, UK). The recombinant plasmid was puriﬁed
using the QIA prep Spin kit (Qiagen) and spectropho-
tometrically quantiﬁed (Qubit, Invitrogen). The copy
number of recombinant plasmids was calculated as
previously described [7] following the formula: N
(molecules per lL) = (C (DNA) lg/lL/K (fragment
size in bp)) · 182.5 · 10
23 (factor derived from the
molecular mass per the Avogadro constant). Serial
10-fold dilutions of both plasmids of known concen-
tration were made and the standard curves were gen-
erated using 1.83 · 10
2 to 1.83 · 10
6 copies of
recombinant plasmid with the M gene fragment from
the pH1N1 and 2.26 · 10
2 to 2.26 · 10
6 of recombi-
nant plasmid with the M gene fragment from
SwH1N1. The limit of detection (LoD) for pH1N1
was 11.65 plasmid copies per reaction, which corre-
sponded to 0.05 TCID50 per reaction. In the case of
the SwH1N1 the LoD was 13.71 copies per reaction,
w h i c hc o r r e s p o n d e dt o0 . 5T C I D 50 per reaction. The
genome equivalent copies (GEC) of plasmid from the
collectedsamplesweredeterminedbasedonthesestan-
dard curves and taking into account their volumes.
Thus, the LoD for pH1N1 was 2.82 log10 GEC and
for SwH1N1 was 2.86 log10 GEC per nasal swab; for
pH1N1theLoDwas4.12log10GECpergramofapical
andmiddlelobesoflungand2.82log10GECpermLof
BAL. Since the efﬁciency of retrotranscription was not
directly determined, GEC numbers did not reﬂect
exactly the number of viral RNA molecules. The RT-
qPCR for SwH1N1 virus was used for samples taken
between day 0 and day 21 PI in the experimental pro-
cedure, whereas RT-qPCR for pH1N1 virus was used
for samples taken between days 21 to 28 PI.
2.9. Sequencing inﬂuenza virus
The complete ampliﬁcation of the PB1, PB2, PA,
HA, NP, MP and NS segments of pH1N1 of the inoc-
ulum (GenBank accession numbers GQ464405-
GQ464411) before and after infection, were obtained
using the genome primer set and protocol recom-
mended by the World Health Organization (WHO)
3.
For SwH1N1, the complete NP segment and the 50
end of the hemagglutinin (HA) segment were also
sequenced before and after infection using the same
set of primers. The ampliﬁed products were analyzed
by agarose gel electrophoresis, stained with SYBR
Gold (MolecularProbes,Eugene,USA)andpuriﬁed
using the NucleoFast 96 PCR kit (MACHEREY-NA-
GELGmbH&CoKG,Du ¨ren,Germany).Sequencing
of both strands was performed using the BigDye tech-
nology (Applied Biosystems), with the primers M13F
(50-TGTAAAACGACGGCCAGT-30)andM13R(50-
CAGGAAACAGCTATGA CC-30). Sequence assem-
blywasaccomplishedusingtheprogramsPhred[3,4],
Phrap and Consed [9], and Bioedit [10]. Homology
andidentitysearcheswithrespecttoinﬂuenzagenome
sequences available at the GenBank were performed
by using the BLAST utilities
4.
2.10. Statistical analysis
The Mann-Whitney test was used to compare
ELISA titres in the different samples tested, and viral
3 http://www.who.int/csr/resources/publications/
swineﬂu/GenomePrimers_20090512.pdf.
4 http://www.ncbi.nlm.nih.gov/BLAST.
SIV cross-protection on A(H1N1) 2009 in pigs Vet. Res. (2010) 41:74
(page number not for citation purpose) Page 5 of 14loads in BAL, nasal swabs and lungs between exper-
imental groups. All analyses were carried out with
NCSS 2004 and PASS 2005 softwares (Kavysville,
Utah, USA). The signiﬁcance level was set at 0.05
with statistical tendencies reported when p <0 . 1 0 .
3. RESULTS
3.1. Clinical outcome
No relevant respiratory or systemic clinical
signs were observed in any pig in any of the
experimental groups. Moreover, no individual
pig showed abnormal rectal temperatures
(  40  C) throughout the duration of the study.
3.2. Pathological studies
Signiﬁcant gross lesions compatible with
BIP were observed in 6 pigs, all of them corre-
sponding to the Mock/pH1N1 group. Remark-
ably, 1 out of 2 pigs sacriﬁced at both 23 and
25 days PI (days 2 and 4 post-pH1N1-inocula-
tion, respectively) had BIP-like lesions. All
remaining Mock/pH1N1 pigs (n =4 )s t u d i e d
on day 28 PI also had BIP-compatible lesions
(Fig. 1A). No gross lesions compatible with
BIP were observed in any pig of the rest of
the groups studied. Besides this, one control
pig (Mock/Mock) euthanized on day 23 PI
had serous arthritis of the left coxo-femoral
joint, one double inoculated animal (SwH1N1/
pH1N1) had ﬁbrous/ﬁbrinous polyserositis
and another SwH1N1/pH1N1 pig had ﬁbrous
pleuritis and mild pulmonary cranio-ventral
scars.
Microscopic pulmonary lesions were
observed in all but the animals from Mock/
Mock group (Figs. 1B and 1C). These lesions
consisted of BIP, characterized by attenuation
and loss of the bronchiolar epithelium, with
mononuclear (lymphocyte and plasma cells)
inﬁltration in the lamina propria of bronchi
and bronchioli, as well as the presence of mac-
rophages and lymphocytes within alveoli sur-
rounding affected bronchi. Sometimes such
inﬂammation also affected the lung interstitium.
Bronchus-associated lymphoid tissue was occa-
sionally hyperplastic. Such BIP lesions were
present in all Mock/pH1N1 pigs, with mild
(n =1 ) ,m o d e r a t e( n = 4) and severe (n =3 )
intensity. Two pigs from each of the
SwH1N1/Mock and SwH1N1/pH1N1 groups
also showed BIP, although intensity was lower;
one pig with mild and another with moderate
lesions in group SwH1N1/Mock, and one ani-
mal with mild and another with mild-to-moder-
ate lesions in group SwH1N1/pH1N1. Average
histopathological BIP score is displayed in
Figure 1D. No histological relevant ﬁndings
were observed in the rest of studied tissues
(nasal turbinates and septae, trachea and tonsil).
3.3. Antibody response against inﬂuenza viruses
Total anti-NP antibody levels, independent
of their isotype, were measured with the compe-
tition ELISA kit in serum from all animals at
the beginning of the assay (day 0), just before
inoculation with pH1N1 (day 21 PI) and seven
days after inoculation with pH1N1 (day 28 PI).
Results represented in Figure 2A show that all
animals were seronegative at the beginning of
the experiment. At day 21 PI, only the animals
in the two groups infected with SwH1N1 SIV
(SwH1N1/Mock and SwH1N1/pH1N1) had
seroconverted and had signiﬁcantly higher anti-
body levels in serum (p = 0.0001) as compared
with the four pH1N1 infected pigs in the Mock/
pH1N1 group, which had total antibody levels
equal or below 60% of inhibition, indicating
that a primary immune response against
pH1N1 was taking place.
No signiﬁcant differences were observed
when antibody levels from the four animals in
group SwH1N1/pH1N1 were compared with
those from group SwH1N1/Mock, although
there was a clear statistical trend (p =0 . 1 1 )t o
suspect that pH1N1 induced a secondary
response. The effect of pH1N1 infection was
further evaluated comparing IgA delta values
between day 21 and 28 between SwH1N1/
Mock and SwH1N1/pH1N1 groups. The
p-value was 0.06, indicating a strong tendency
close to signiﬁcance. Moreover, this tendency
was also observed when serum samples were
analyzed for speciﬁc IgA (Fig. 3A) and IgG
(Fig. 3B) anti-NP antibodies in all the animals
although to a lesser extent.
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predominantly mediated by antibodies against
HA. Thus, serum samples were examined by
HI assays against SwH1N1 and pH1N1
(Tab. II) at day 0, 21 and 28 PI. All animals in
thegroupinfectedbySwH1N1exhibitedHIanti-
bodytitresatday21 PI,whichremainedconstant
untilday28 PI.Inthecaseof3outof4animalsin
group Mock/pH1N1, some low level of HI anti-
bodies were present at day 28 PI (7 days after
pH1N1infection).However,withoneexception,
HI titres elicited by SwH1N1/pH1N1 animals
exhibited an increment between day 21 and
28 PI when tested against SwH1N1. Also, HI
antibody titres in the SwH1N1/pH1N1 group
were higher than those observed in the animals
from SwH1N1/Mock group (Tab. II). All sera
collected at day 21 PI remained negative for
HI when tested against pH1N1, with the excep-
tion of animal 152. However, at day 28 PI, HI
titres against pH1N1 from animals of the
SwH1N1/pH1N1 group were higher than for
the Mock/pH1N1 group. Surprisingly, one ani-
mal (178) gave low serum responses in ELISA
and HI tests, but exhibited high antibody OD
ratios against the NP at the nasal cavity.
Figure 1. Pathological analysis at day 28 PI. (A) A representative picture of lung from group Mock/
pH1N1. The lungs show moderate broncho-interstitial pneumonia (BIP)-compatible lesions. (B) Lung from
a Mock/Mock control pig. Normal pulmonary parenchyma. Note the minimal thickness of interalveolar
walls, characterised by pneumocytes and blood capillaries. Peribronchial lymphoid tissue is minimally
developed. Haematoxylin and eosin stain. Bar = 200 lm. (C) Lung from a pH1N1 infected pig (day 7 post-
pH1N1 inoculation). Marked presence of mononuclear inﬂammatory cells within alveoli, almost collapsing
alveolar lumen. Lymphocyte perivascular cufﬁng together with moderate hyperplasia of the lymphoid tissue
surrounding a bronchioli. Haematoxylin and eosin stain. Bar = 200 lm. (D) Pathological score for all the
animals in the assay ( Mock/Mock, Mock/pH1N1, SwH1N1/Mock, SwH1N1/pH1N1).
(A color version of this ﬁgure is available at www.vetres.org.)
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were also detected in BAL of Mock/pH1N1
animals at tested times (23, 25 and 28 days
PI, which were day 2, 4 and 7 PI for pH1N1
infection) (Fig. 4).
3.4. Viral RNA quantiﬁcation
Viral RNA levels were investigated in respi-
ratory tissues. SwH1N1 RNA was detected in
nasal swabs of pig groups SwH1N1/Mock
and SwH1N1/pH1N1 from day 1 to 7 PI, and
had the maximum viral RNA load between
days 2 and 4 PI (Figs. 5A and 5C). No viral
RNA was detected on days 10 and 21 PI and
in any day PI in the remaining groups (Mock/
Mock and Mock/pH1N1). Similarly, pH1N1
R N Aw a sd e t e c t e db e t w e e n1a n d7d a y sP I
with this virus, with a peak load between days
2a n d4P I( Fig. 5B). No pH1N1 viral RNAwas
detected in any of the samples in group
SwH1N1/pH1N1 at any of the time-points ana-
lyzed after pH1N1 inoculation or in the rest of
the animal groups (Mock/Mock and SwH1N1/
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Figure 2. Antibodies in serum and nasal swabs.
(A) Inﬂuenza total anti-NP antibodies in serum
were analyzed by ELISA competition assay.
(B) Inﬂuenza IgA anti-NP antibodies in nasal
swabs were analyzed by ELISA at day 0, 21 and
28 PI. White squares, white rhomboids, white
triangles and black circles represent average values
from animals belonging to Mock/Mock (h),
SwH1N1/Mock (e), Mock/pH1N1 (D) and
SwH1N1/pH1N1 (d) group, respectively. Error
bars represent one SD above and below the mean.
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Figure 3. IgA and IgG antibodies in serum. (A)
Inﬂuenza IgA and (B) IgG anti-NP antibodies in
serum were analyzed by ELISA at day 0, 21 and 28
PI. White squares, white rhomboids, white triangles
and black circles represent mean values from
animals belonging to Mock/Mock (h), SwH1N1/
Mock (e), Mock/pH1N1 (D) and SwH1N1/pH1N1
(d) groups, respectively. Error bars represent one
SD above and below the mean.
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Page 8 of 14 (page number not for citation purpose)Figure 4. IgA and IgG antibodies in BAL. Inﬂuenza IgA and IgG anti-NP antibodies in BAL were
analyzed by ELISA at day 23, 25 and 28 PI (corresponding to day 2, 4 and 7 after pH1N1 inoculation).
White bars and dotted bars represent average IgA values of 2 and 4 animals belonging to Mock/Mock and
Mock/pH1N1 groups, respectively. Black bars and lined bars represent average IgG values of 2 and 4
animals belonging to Mock/Mock and Mock/pH1N1 groups, respectively. Error bars represent one SD
above and below the mean.
Table II. Individual hemagglutination inhibition titres from sera belonging to animals from different
infection groups (Mock/Mock, SwH1N1/Mock, Mock/pH1N1 and SwH1N1/pH1N1). Samples were tested
for hemagglutinin antigens from the viruses used in the experimental infection (SwH1N1 and pH1N1).
Animal number SwH1N1 (A/Swine/Spain/
53207/2004)
pH1N1 (A/Catalonia/63/
2009)
d0 d21 d28 d0 d21 d28
Mock/Mock 160 < 20 < 20 < 20 < 20 < 20 < 20
186 < 20 < 20 < 20 < 20 < 20 < 20
SwH1N1/Mock 87 < 20 160 160 < 20 < 20 < 20
152 < 20 160 160 < 20 20 < 20
153 < 20 160 160 < 20 < 20 < 20
159 < 20 160 160 < 20 < 20 < 20
Mock/pH1N1 82 < 20 < 20 < 20 < 20 < 20 40
180 < 20 < 20 < 20 < 20 < 20 40
188 < 20 < 20 < 20 < 20 < 20 20
200 < 20 < 20 < 20 < 20 < 20 < 20
SwH1N1/pH1N1 84 < 20 160 320 < 20 < 20 80
86 < 20 80 640 < 20 < 20 320
168 < 20 80 320 < 20 < 20 80
178 < 20 80 80 < 20 < 20 < 20
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animals from group Mock/pH1N1 compared
with those from SwH1N1/pH1N1 animals on
days 22, 23 and 25 of the experiment were
statistically signiﬁcant (p =0 . 0 2 ;p = 0.02 and
p = 0.004, respectively).
Inﬂuenza RNA load was also analyzed in the
lungs (apical and cardiac lobes) of animals
(SwH1N1/Mock)
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Figure 5. Inﬂuenza viral RNA load in nasal swabs. Quantiﬁcation of inﬂuenza RNAwas performed by RT-
qPCR at the indicated days PI. Bars indicate average values of positive samples in genome equivalent
copies (GEC) of plasmid per swab in group SwH1N1/Mock (A), Mock/pH1N1 (B) and SwH1N1/pH1N1
(C). The number of positive samples from the total number of animals was indicated above each bar.
Samples from animals in group Mock/Mock were all below the limit of detection, which is indicated by the
dotted line. Error bars represent one SD above and below the mean.
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and SwH1N1/pH1N1 on days 23, 25 and 28 of
the experiment (corresponding to day 2, 4 and
7 after pH1N1 infection) (Fig. 6A). No viral
RNA was detected in the lungs of any animal
belonging to the Mock/Mock group or
SwH1N1/pH1N1groupinanylungtissuetested.
Differences between viral RNA load in animals
from groupMock/pH1N1 comparedwith values
from lung from group SwH1N1/pH1N1 on days
22, 25 and 28 of the experiment were signiﬁ-
cantly different (p = 0.03). Inﬂuenza RNA was
also detected in BAL from most of the animals
in Mock/pH1N1 group (Fig. 6B)w h e r e a sn o
viral RNA was found in BAL from animals in
Mock/Mock group.
3.5. Sequencing of SwH1N1 and pH1N1
The complete NP segment and the 5’ end of
HA sequences of SwH1N1 were analyzed and
showed 100% identity to those reported previ-
ously (CY010583 and CY010580). Secondly,
sequences of the complete PB2, PB1, PA,
HA, NP, MP and NS genes of pH1N1 used
for infection showed no variation when com-
pared to other pandemic viruses. Furthermore,
the sequences of pH1N1 isolated after pig
infection were identical to those of the pH1N1
inoculum. Comparison of amino acid sequences
from SwH1N1 with pH1N1 sequences resulted
in an NP homology of 92% whereas in the case
of HA this value was 78% and for NA it was
96%.
4. DISCUSSION
In the present study, the possible protective
effect of an infection with a circulating Euro-
pean avian-like swine A/Swine/Spain/53207/
2004 (H1N1) inﬂuenza virus (referred to as
SwH1N1) in colostrum-deprived pigs was eval-
uated against a subsequent infection with the
new human A/Catalonia/63/2009(H1N1) inﬂu-
enza virus (referred to as pH1N1). A prior expo-
sure to the SwH1N1 strain induced immunity
able to substantially reduce if not inhibit
pH1N1 shedding and viral RNA load in respira-
tory tissues after a subsequent pH1N1 infection
even in the absence of detectable cross-HI anti-
bodies. It also protected pigs from lesion devel-
opment. Additionally, previous results from
studies of pigs infected with the new human
A(H1N1) 2009 inﬂuenza virus were conﬁrmed
in the present work. The results presented here
show that intranasal infection of pigs with
10
6.15 TCID50 of pH1N1 virus exhibited mild
to moderate lung lesions, resulting in virus
shedding and activation of a speciﬁc humoral
immune response, as it has been previously
shown [16].
Thetypicalinﬂuenza-likesymptomswerenot
observed in either group Mock/pH1N1 or
SwH1N1 infected animals used in the present
experiment. Such a situation should not be
surprising, since clinical signs including fever
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Figure 6. Inﬂuenza viral load in lung tissues and
BAL. Quantitation of inﬂuenza RNAwas performed
by RT-qPCR at day 23, 25 and 28 PI (corresponding
to day 2, 4 and 7 after pH1N1 inoculation). Bars
indicate average values of positive samples in
genome equivalent copies (GEC) of plasmid per
swab in group Mock/pH1N1 for lung tissue (A) and
BAL (B). The number of positive samples from the
total number of animals was indicated above each
bar. Samples from animals in groups Mock/Mock
and SwH1N1/pH1N1 were all below the detection
limit, indicated by the dotted line. Error bars
represent one SD above and below the mean.
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ulation was performed with a high virus dose
(  7.5 log10 TCID50)[ 23, 24]. Therefore, the
experimentalconditionsusedhereinducedasub-
clinical infection, a situation very often encoun-
tered on farms as most of SIV infections in
ﬁeldconditionscausesubclinicalinfections[14].
After infection, virus RNA load in nasal
swabs was detected very rapidly (at day 1 PI)
not only for SwH1N1 but also for pH1N1.
These results are in line with previous data
showing that pigs are susceptible to the novel
inﬂuenza virus A(H1N1) 2009 and they are
able to infect contact pigs as soon as 3 days
PI [16]. They also support data obtained from
a naturally infected swine herd [28]. Thus, it
is conceivable that this virus would probably
spread quickly and efﬁciently if introduced
into SIV H1N1 free farms. Reports from 19
countries world wide
1 about putative human-
to-pig transmissions and also experimental
studies of sequential passages of the virus in
pigs [1] support this observation. However,
the data presented in this work indicated that
a previous infection with at least one circulating
European avian-like H1N1 SIV strain would
decrease the risk of a further infection with
A(H1N1) 2009, and consequently, the potential
of further reassorting.
Antiviral adaptive immune mechanisms
against inﬂuenza virus involve neutralizing anti-
bodies, including secretory IgA at mucosal sur-
faces, and CTL. Interestingly, primary inﬂuenza
virus infection in pigs induced local antigen-
speciﬁc lymphoproliferative responses and a
long-lived increase of lung CD8
+ T cells which
could play a role in the broad-spectrum immune
protectiontoheterotypicvirusstrains[11].How-
ever, humoral protection against inﬂuenza
viruses is mainly mediated by antibody
responses to HA [17]. In a previous study, pigs
immunized as a result of intranasal inoculation
with either H1N1 or H3N2 showed partial
clinical protection against H1N2 challenge, and
nasal and virus shedding was two days shorter
than in naı ¨ve pigs [20]. Later, Heinen et al. [11]
reported some heterotypic immunity in animals
infected by aerosol ﬁrstly with H1N1 and later
with H3N2. However, no cross-reactive HI
antibodies from SIV H1N1-infected pigs were
observed with H3N2 SIVor vice versa after pri-
mary infection. A recent report on serologic
cross-reactivity with A (H1N1) 2009 in pigs
serum showed that consecutive infection with
two European SIV subtypes induced HI cross-
reacting antibodies to A(H1N1) inﬂuenza virus,
even though European viruses do not contain a
classical swine H1 HA. These authors also
described that HI antibodies induced by a single
infectionwithEuropeansubtypeH1N1orH1N2
SIV did not cross-react with the pandemic
(H1N1) 2009 virus [15]. The results presented
in this work are in full agreement with all these
previous data as no cross-reactive antibodies
were detected between SwH1N1 and pH1N1
before pH1N1 infection. These results suggest
that sequence divergence of around 20–30% in
amino acids in proteins such as HA or NA do
not interfere with the generation of memory
cross-reactive B cells.
Furthermore, the sequences of pH1N1 inoc-
ulated and pH1N1 isolated from infected pigs
were identical, suggesting that the virus did
not evolve within the study period. This is in
agreement with data obtained so far in humans
where genetic variability of the virus is very
limited. However, recent information from a
naturally infected swine herd with A(H1N1)
2009 suggested that either a higher than normal
mutation rate, strong positive selective pressure,
or a combination of both might apply for this
infection [28]. Further work will elucidate the
genetic evolution of this new virus.
Davenport et al. [2] ﬁrst described in 1953
the phenomenon of original antigenic sin. This
observation was later expanded showing that
the phenomenon of original antigenic sin
responses to inﬂuenza viruses existed not just
in humans but in other species as well [5, 6,
26]. In the context of sequential infection with
two inﬂuenza viruses, the primary exposure
induces proliferation of B cells that are either
speciﬁc for the ﬁrst virus only or cross-reactive
with both viruses. Upon exposure to the second
virus, memory B cells cross-reactive to both
viruses outcompete naı ¨ve B cell clones just spe-
ciﬁc for novel epitopes from the second virus.
Indeed, this theoretical explanation would ﬁt
with the results obtained in the present study,
showing that original antigenic sin also takes
Vet. Res. (2010) 41:74 N. Busquets et al.
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memory B cells for SwH1N1 and pH1N1
might be generated upon infection with
SwH1N1 by a single SwH1N1 exposure. The
fact that cross-reacting antibodies were unde-
tected before pH1N1 infection indicated that
this cross-reactive memory B cell population
was a minor population. These memory cells
would be later activated by differentiating into
plasma B cells when pH1N1 infection took
place, explaining the rapid increase in pH1N1
speciﬁc HI antibodies 7 day after pH1N1 infec-
tion in animals from group SwH1N1/pH1N1
compared with HI antibodies titres in animals
only infected with pH1N1 (primary infection)
and the higher values of HI antibodies against
SwH1N1 at day 28 (Tab. II).
In the present experiment, the boosting
effect of pH1N1 infection in group SwH1N1/
pH1N1 for IgA levels at mucosal sites and
the HI cross-reactive antibodies generated after
challenge would suggest that humoral
responses with cross-neutralizing activity in
respiratory tissues and sera played a major role
in conferring protective immunity. Therefore, it
seems that speciﬁc humoral immunity, particu-
larly the one induced at the respiratory mucosa,
correlated with protection in animals challenged
with a subsequent infection with pH1N1.
To the authors’ knowledge, this is the ﬁrst
study in which immunity generated against a
circulating European avian-like swine (H1N1)
inﬂuenza virus in pigs has been evaluated
against a subsequent infection with a human
(H1N1) inﬂuenza virus in pigs. In summary, a
previous infection with one of the European cir-
culating H1N1 SIVin the ﬁeld was able to con-
fer protective immunity to pigs against a
challenge with the new variant A(H1N1)
2009. These data pave the way for under-
standing cross-protective immune responses
generated between different inﬂuenza viral
infections, within the same subtype or different
subtypes. Further characterizations are required
to understand the whole picture and all the ﬁne
mechanisms involved in cross-protection.
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